Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a Phase 3, open-label, multi-center, interventional safety study of REM therapy in participants 12 years of age or older with COVID-19, pneumonia and oxygen supplementation.
Description: The primary endpoint of the study is the proportion of patients with at least one treatment-emergent AESI (hypersensitivity including infusion-related reaction, anaphylactic reaction, acute respiratory failure, hypotension, hepatic toxicity and nephrotoxicity).
Measure: To assess the safety and tolerability of REM use in Hungary in the conditionally approved indication (EMA) Time: 30 daysDescription: the proportion of patients with at least 1 treatment-emergent adverse event
Measure: Secondary safety endpoints <1> Time: 30 daysDescription: proportion of patients with treatment-emergent clinical laboratory abnormalities (separately for the following parameters: ALT, AST, INR, HGB, Bilirubin, ALP, Creatinine, eGFR)
Measure: Secondary safety endpoints <2> Time: 30 daysDescription: time to recovery (days)
Measure: The secondary efficacy endpoint <3> Time: 30 daysDescription: time to discharge from hospital (days)
Measure: The secondary efficacy endpoint <4> Time: 30 daysDescription: number and proportion of patients at prespecified timepoints in each category of the WHO Ordinal Scale for Clinical Improvement
Measure: The secondary efficacy endpoint <5> Time: 30 daysDescription: number and proportion of patients at prespecified timepoints in each category (Ambient air, Low flow, Medium Flow, High Flow, Non invasive ventilation, Invasive ventilation, ECMO)
Measure: The secondary efficacy endpoint <6> Time: 30 daysDescription: proportion of participants with normalization of fever
Measure: The secondary efficacy endpoint <7> Time: 30 daysDescription: proportion of participants with normalization of oxygen saturation (>=95%) through Day 10 with 14 days follow-up after the last dose
Measure: The secondary efficacy endpoint <8> Time: 30 daysDescription: Number and proportion of patients at prespecified timepoints in each category of the 8-point ordinal scale of disease severity.
Measure: Exploratory endpoints <1> Time: 30 daysDescription: Proportion of patients with clinically relevant improvement in radiological findings as assessed by the investigator at discharge from hospital
Measure: Exploratory endpoints<2> Time: 30 daysDescription: Proportion of patients with COVID19 complications/remaining symptoms as assessed by the investigator at discharge from hospital
Measure: Exploratory endpoints<3> Time: 30 daysDescription: Proportion of patients with at least one treatment- or intervention-related adverse event.
Measure: Exploratory endpoints<4> Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports